Urolithin A Choline Salt Type A is a salt-form option for ingredient evaluation. For supplement brands, OEM/ODM teams and distributors, the practical question is how its material properties fit a proposed formula. This guide connects the research background with reported solubility data, a rat pharmacokinetic comparison and the questions to resolve before sourcing.
The company technical profile describes choline as the counterion and Type A as the selected crystalline form. Salt formation and crystal-form selection are part of the material development strategy. Confirm the identity of the supplied ingredient through its specification and analytical documentation.
When comparing materials, distinguish total salt mass from the amount of the Urolithin A component. This affects how analytical results, study quantities and formulation loadings should be interpreted. Laboratory and animal findings provide a starting point for development; they do not establish clinical efficacy for the salt.
A randomized trial investigated a specific urolithin A preparation in 66 older adults. Selected muscle endurance measures improved at two months, while the primary outcomes of six-minute walking distance and maximal ATP production in hand muscle did not improve significantly versus placebo. The tested preparation was not Urolithin A Choline Salt Type A.
The publication provides scientific background for ingredient evaluation. It does not establish efficacy, safety or a use level for the choline salt. Product-specific conclusions require evidence appropriate to the supplied material and intended use.
The company technical profile reports comparisons in simulated intestinal fluid and purified water. Test medium and sampling time are essential parts of each result.
In the FaSSIF test, 3.60 divided by 0.28 gives a ratio of approximately 12.9, or about 13 times the reported free-form value. In purified water, the Type A result corresponds to about 1.54 mg/mL. An exact water-solubility ratio cannot be calculated because the numerical detection limit for the free-form result is not specified. [1]
These reported measurements can inform formulation screening. They do not establish that the material will remain dissolved at every concentration, pH or storage condition. Ask for the test method and run a comparison in the intended product matrix before selecting a liquid or dispersible format.
The reported rat oral study compares exposure over the measured sampling period, peak plasma concentration and the time to that peak. The table presents the reported central values.
The central-value ratios are approximately 2.16 for AUC and 4.95 for Cmax. An AUC ratio of 2.16 means 216% of the comparator value, equivalent to an increase of about 116%. It does not mean a 216% increase. A shorter Tmax describes the timing of the measured concentration peak, not a demonstrated faster onset of a health benefit. [1]
Interpretation requires the complete protocol, including dose basis, formulation vehicle, measured analyte and sampling window. These are preclinical exposure findings. The ratios do not establish a human-use level or product performance in humans.
Start with one format and a measurable development objective. For example, an OEM can compare powder handling and fill consistency, while a brand investigating a dispersible product can define a target concentration and an acceptable sedimentation profile. The test plan should reflect the actual finished product.
A useful supplier discussion begins with a common specification and a clear development brief. Request the following items relevant to your project:
1.Chemical identity and solid-form characterization, with the applicable test methods.
2.A current specification and representative batch certificate of analysis.
3.The basis of purity and assay results, including how UA content and total salt mass are reported.
4.Solubility and exposure reports with experimental conditions and comparator details.
5.Stability information, proposed packaging and supporting storage data.
6.Current sample availability, minimum order quantity, lead time and quotation against the same specification.
